Ignyta, a VC-backed, San Diego-based developer of products and services for the treatment of autoimmune diseases, received a $1 million capital term loan facility from Silicon Valley Bank. The financing will enable Ignyta to continue its development of a biomarker-based test used to detect the earliest stages of rheumatoid arthritis. Founded in 2011, Ignyta previously raised $6.3 million in two rounds of VC funding.
